Clinical Trials Logo

Coronary Vasospasm clinical trials

View clinical trials related to Coronary Vasospasm.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02653222 Terminated - Clinical trials for Kidney Failure, Chronic

Chemical Renal Ethanol Sympatholysis Under CT Guidance Use for the Control of Therapy-Resistant Hypertension

SCRATCH
Start date: February 2016
Phase: Phase 2
Study type: Interventional

In this study the investigators are going to assess the feasibility of this innovate technique of renal sympathetic denervation by translumbar access under ct-guidance. To limit the potential impact on the kidney, the investigators chose a population of chronic renal failure patients on dialysis or renal transplant (with native kidneys still present) and having resistant treatment hypertension despite antihypertensive combination therapy well conducted. The investigators expect to obtain a decrease of the blood pressure at the 24-hours ambulatory blood pressure monitoring (ABPM) one month after the sympathetic denervation.

NCT ID: NCT02559882 Terminated - Clinical trials for Hypertension, Resistant to Conventional Therapy

How to Test Success of a Renal Denervation

Start date: August 2015
Phase:
Study type: Observational

The study aimed to assess the success of a clinically indicated renal denervation by different tests and correlate the results of the tests with the clinical outcome.

NCT ID: NCT02539810 Terminated - Hypertension Clinical Trials

Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)

ANDORRA
Start date: September 2015
Phase: Phase 4
Study type: Interventional

The ANDORRA study is a, multicenter, prospective, open, randomized, controlled blinded endpoint trial (PROBE) comparing two treatment strategies (renal artery stenting + standardized and optimized medical treatment [SOMT] versus SOMT alone) of 12 months duration in patients with confirmed resistant hypertension (RH) and angiographically proven grade III unilateral or bilateral atherosclerotic renal artery stenosis (ARAS) ≥ 60%.